Retina dose as a predictor for visual acuity loss in 106Ru eye plaque brachytherapy of uveal melanomas

Publication date: Available online 13 February 2018
Source:Radiotherapy and Oncology
Author(s): Gerd Heilemann, Lukas Fetty, Matthias Blaickner, Nicole Nesvacil, Martin Zehetmayer, Dietmar Georg, Roman Dunavoelgyi
Background and purposeTo evaluate the retina dose as a risk factor associated with loss of visual acuity (VA) in ¹⁰⁶Ru plaque brachytherapy.Material/methods45 patients receiving ¹⁰⁶Ru plaques brachytherapy (median follow-up 29.5 months) were included in this study. An in-house developed treatment planning system with Monte Carlo based dose calculation was used to perform treatment planning and dose calculation. Risk factors associated with loss of VA were evaluated using the Cox proportional hazards models, Kaplan–Meier estimates and Pearson correlation coefficients.ResultsA significant correlation was found between VA loss and mean (r = 0.49, p = 0.001) and near maximum (r = 0.47, p = 0.001) retina dose D2% and tumor basal diameter (r = 0.50, p < 0.001). The Kaplan–Meier and Cox proportional hazards model yielded a significantly higher risk for VA loss (>0.3Snellen) for patients receiving a maximum dose of >500 Gy (p = 0.002). A Cox multivariate analysis including the macula dose (p = 0.237) and basal diameter (p = 0.791) showed that a high maximum retinal dose is the best risk factor (p = 0.013) for VA loss.ConclusionThe study showed that retina dose (D2% and Dmean) is a suitable predictor for VA loss.



http://ift.tt/2EqosYt